AstraZeneca PLC Share Price and Company Fundamentals



Price
£7895
Change
31.000 (0.394%)
52 week
71.46 - 10120.0

Last traded: Today at 3:35 PM

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; and Alchemab to enhance prostate cancer research. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Key Metrics

PE ratio

36.72

PB ratio

717.86

Dividend yield

0.04%

Beta

0.21

Market cap

£103.64B

Enterprise value

£117.91B

Company profile

Industry / SectorDrug Manufacturers—General / Healthcare
Full time employees76100
Websitehttp://www.astrazeneca.com
Mailing address1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom
Phone / Fax44 20 3749 5000 /

Dividends

Dividend yield

0.04%

Dividend amount

£2.80

Payout ratio

93.81%

5Y Avg. yield

3.62%

AstraZeneca PLC paid £2.80 dividend and the ex-dividend date was 25 Feb 2021.The dividend payout ratio is 93.81%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AZN dividend payout ratio is more than 90% making it difficult for the company to maintain the dividends and increase it year by year.

AZN's forward dividend amount is £2.07 and the forward dividend yield is 2.63%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of May 2021, following are the company executives and directors listed on AstraZeneca PLC.

NameTitleAgeTotal Pay
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director614.39M
Mr. Marc DunoyerCFO & Exec. Director682.45M
Ms. Pam P. ChengExec. Vice-Pres of Operations & Information Technology49
Thomas Kudsk LarsenHead of Investor Relations
Mr. Jefrey PottExec. VP of HR & Gen. Counsel
Ms. Katarina AgeborgExec. VP of Sustainability & Chief Compliance Officer
Dr. Menelas PangalosExec. Vice-Pres of BioPharmaceuticals R&D
Dr. Ruud DobberExec. Vice-Pres of BioPharmaceuticals Bus. Unit
Dr. Susan Mary Galbraith M.D., Ph.D.Sr. VP and Head of Research, Early Devel. & Oncology R&D54
Dr. David B. Goldstein Ph.D.Chief Adviser

Profitability and management effectiveness

Profit margin

14.42%

Operating margin

14.85%

Return on assets

4.19%

Return on equity

29.67%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of AstraZeneca PLC is 103.64B and its enterprise value is 117.91B. The enterprise value to revenue ratio of AZN is 4.28.

The AZN's stocks Beta value is 0.21 making it 79% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

AstraZeneca PLC (LSE:AZN) Frequently Asked Questions

1. What is AstraZeneca PLC's Stock Symbol?

AstraZeneca PLC trades on LSE under the ticker symbol "AZN".

2. What is AstraZeneca PLC's stock price today?

One share of AZN stock can currently be purchased for approximately £7895.

3. How can I contact AstraZeneca PLC?

AstraZeneca PLC's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom. The company can be reached via phone at 44 20 3749 5000.

4. What is AstraZeneca PLC's official website?

The official website of AstraZeneca PLC is http://www.astrazeneca.com.